(+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride | 2650481-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride
• 英文别名: (R)-(4-imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]triazin-2-yl)-dimethylamine hydrochloride；Imeglimin hydrochloride；(4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine;hydrochloride
• CAS: 2650481-44-8
• 化学式: C₆H₁₃N₅*ClH
• 分子量: 191.664
• InChiKey: UXHLCYMTNMEXKZ-PGMHMLKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.41
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  66
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine tartrate 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 生成 (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine hydrochloride
  参考文献：
  名称：

  SEPARATION OF TRIAZINE DERIVATIVES ENANTIOMERS USING TARTARIC ACID

  摘要：

  本发明涉及一种使用酒石酸分离三嗪衍生物对映体的新工艺。

  公开号：

  US20130261300A1

文献信息

• [EN] PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5 TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION<br/>[FR] PROCÉDÉ DE SÉPARATION DES ÉNANTIOMÈRES DE DIHYDRO-1,3,5-TRIAZINES RACÉMIQUES PAR CRISTALLISATION PRÉFÉRENTIELLE
  申请人：POXEL

  公开号：WO2010109015A1

  公开（公告）日：2010-09-30

  A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.

  一种新的工艺，通过优先结晶对外消旋3,6-二氢-1,3,5-三嗪衍生物进行对映异构体分离，用于治疗与胰岛素抵抗综合症相关的疾病。
• Imeglimin for preventing and/or treating hepatocellular carcinoma
  申请人：Janin Eric

  公开号：US11324752B2

  公开（公告）日：2022-05-10

  Use of imeglimin for the prevention and/or treatment of hepatocellular carcinoma.

  使用伊迈格列明预防和/或治疗肝细胞癌。
• [EN] SEPARATION OF TRIAZINE DERIVATIVES ENANTIOMERS USING TARTARIC ACID<br/>[FR] SÉPARATION DES ÉNANTIOMÈRES DE DÉRIVÉS DE TRIAZINE EN UTILISANT L'ACIDE TARTRIQUE
  申请人：POXEL

  公开号：WO2012072663A9

  公开（公告）日：2012-08-30
• PROCESS OF ISOLATING ENANTIOMER COMPONENTS FROM ENANTIOMER MIXTURES BY PARTICLE-SIZE-CONTROLLED CRYSTALLIZATION
  申请人：Poxel

  公开号：EP2344435B1

  公开（公告）日：2016-03-23
• PROCESS OF ISOLATING ENANTIOMER COMPONENT FROM ENANTIOMER MIXTURES BY PARTICLE-SIZE-CONTROLLED CRYSTALLIZATION
  申请人：Maillard David

  公开号：US20110184169A1

  公开（公告）日：2011-07-28

  The present invention discloses a process for isolating enantiomer components from a mixture of enantiomers through particle-size-controlled crystallization, comprising the steps of: (a) forming a solution of a mixture of enantiomers (R) and (S) in a solvent in the absence of any further additives or agents; (b) seeding the solution of step (a) simultaneously or consecutively with seed crystals of enantiomer (R) and with seed crystals of enantiomer (S), wherein the seed crystals of enantiomer (R) differ in size and/or in quantity from the seed crystals of enantiomer (S) to allow separation of the crystals composed of a mixture enriched with enantiomer (R) from the crystals composed of a mixture enriched with enantiomer (S); (c) inducing simultaneous crystallization of enantiomer (R) and enantiomer (S); and (d) isolating crystals composed of a mixture enriched with enantiomer (R) from crystals composed of a mixture enriched with enantiomer (S) through size separation of the crystals, preferably through sieving, melting or sedimentation, in particular through sieving.